Kedudukan dalam Saham
#16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Perubahan (1 tahun)
-14.35%
Perdagangan Valbiotis SA (ALVAL)
Harga ALVAL dengan permodalan pasaran b
Modal pasaran bagi Valbiotis SA(ALVAL)
Modal Pasaran: $22.26M
Sehingga July 2026, Valbiotis SA mempunyai modal pasaran sebanyak $22.26M. Ini menjadikan Valbiotis SA syarikat ke-16324th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Valbiotis SA dari 2017 hingga 2026
ALVAL berbanding dengan 5 teratas yang paling popular stocks
| Harga ALVAL |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.130T
|
+23,040,964.32%
|
|
|
|
|
$4.624T
|
+20,770,336.50%
|
|
|
|
|
$4.348T
|
+19,529,650.77%
|
|
|
|
|
$2.859T
|
+12,842,806.05%
|
|
|
|
|
$2.662T
|
+11,957,316.93%
|
